{"entity":{"id":"euvax-b","kind":"drug","name":"Euvax B (hepatitis B vaccine, LG Chem)","aka":[],"tldr":"LG Chem's hepatitis B vaccine from South Korea, prequalified by WHO since 1996 and available to national immunisation programmes through UN procurement.","summary":"WHO's list of prequalified vaccines carries Euvax B (LG Chem Ltd, regulated by Korea's Ministry of Food and Drug Safety) as a hepatitis B vaccine in one- and ten-dose vials, prequalified on 22 November 1996, and a paediatric presentation prequalified on 21 January 2020. It is not in the FDA Purple Book or the EMA medicines report.\n\nWhy it is a cancer vaccine: WHO estimates that hepatitis B caused 1.1 million deaths in 2024, mostly from cirrhosis and hepatocellular carcinoma (primary liver cancer), and that infection in infancy and early childhood becomes chronic in about 95% of cases. WHO recommends that all babies receive the vaccine as soon as possible after birth (within 24 hours), followed by two or three further doses (WHO fact sheet, 28 July 2026).","status":"established","asOf":"2026-11-04","links":[{"label":"WHO list of prequalified vaccines (CSV export)","url":"https://extranet.who.int/prequal/vaccines/prequalified/export?page&_format=csv"},{"label":"WHO fact sheet: hepatitis B (28 July 2026)","url":"https://www.who.int/news-room/fact-sheets/detail/hepatitis-b"}],"tags":["preventive-vaccine","hepatitis-b-vaccine"],"related":["bevac","sii-hepatitis-b-vaccine","heberbiovac-hb","engerix-b","who-prequalified-vaccines"],"cancers":[],"sections":["prevention"],"technologies":["hpv-vaccine"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["hbv-hcv"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"brand":"Euvax B","modality":"Prophylactic vaccine (recombinant)","mechanism":"Recombinant hepatitis B surface antigen (the active substance the regulators name) trains the immune system to make antibodies against hepatitis B virus, preventing the infection that can lead to liver cancer.","approvals":[{"region":"WHO","year":1996,"indication":"WHO prequalification, hepatitis B vaccine (paediatric presentation prequalified 2020)"}],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[{"date":"1996-11-22","type":"approval","region":"WHO","note":"WHO prequalification (WHO list of prequalified vaccines)","source":"https://extranet.who.int/prequal/vaccines/prequalified/export?page&_format=csv"}]},"route":"/drugs/euvax-b/","neighbours":{"drug":[{"id":"bevac","kind":"drug","name":"BEVAC hepatitis B vaccine (Biological E)","route":"/drugs/bevac/"},{"id":"engerix-b","kind":"drug","name":"Engerix-B (hepatitis B vaccine, recombinant)","route":"/drugs/engerix-b/"},{"id":"heberbiovac-hb","kind":"drug","name":"Heberbiovac HB (hepatitis B vaccine, Cuba)","route":"/drugs/heberbiovac-hb/"},{"id":"sii-hepatitis-b-vaccine","kind":"drug","name":"Hepatitis B Vaccine (rDNA), Serum Institute of India","route":"/drugs/sii-hepatitis-b-vaccine/"}],"collection":[{"id":"who-prequalified-vaccines","kind":"collection","name":"WHO list of prequalified vaccines","route":"/collections/who-prequalified-vaccines/"}],"section":[{"id":"prevention","kind":"section","name":"Prevention & Risk","route":"/fronts/prevention/"}],"technology":[{"id":"hpv-vaccine","kind":"technology","name":"HPV & HBV vaccination","route":"/technologies/hpv-vaccine/"}],"term":[{"id":"hbv-hcv","kind":"term","name":"Hepatitis B and C as cancer causes","route":"/terms/hbv-hcv/"},{"id":"hepatitis-b-birth-dose-programmes","kind":"term","name":"Hepatitis B birth-dose vaccination by country","route":"/terms/hepatitis-b-birth-dose-programmes/"}]}}